Literature DB >> 25644007

Dendritic cell-based immunization ameliorates pulmonary infection with highly virulent Cryptococcus gattii.

Keigo Ueno1, Yuki Kinjo2, Yoichiro Okubo3, Kyoko Aki3, Makoto Urai1, Yukihiro Kaneko4, Kiminori Shimizu5, Dan-Ni Wang6, Akiko Okawara1, Takuya Nara1, Kayo Ohkouchi1, Yuki Mizuguchi1, Susumu Kawamoto5, Katsuhiko Kamei7, Hideaki Ohno8, Yoshihito Niki9, Kazutoshi Shibuya3, Yoshitsugu Miyazaki1.   

Abstract

Cryptococcosis due to a highly virulent fungus, Cryptococcus gattii, emerged as an infectious disease on Vancouver Island in Canada and surrounding areas in 1999, causing deaths among immunocompetent individuals. Previous studies indicated that C. gattii strain R265 isolated from the Canadian outbreak had immune avoidance or immune suppression capabilities. However, protective immunity against C. gattii has not been identified. In this study, we used a gain-of-function approach to investigate the protective immunity against C. gattii infection using a dendritic cell (DC)-based vaccine. Bone marrow-derived dendritic cells (BMDCs) efficiently engulfed acapsular C. gattii (Δcap60 strain), which resulted in their expression of costimulatory molecules and inflammatory cytokines. This was not observed for BMDCs that were cultured with encapsulated strains. When Δcap60 strain-pulsed BMDCs were transferred to mice prior to intratracheal R265 infection, significant amelioration of pathology, fungal burden, and the survival rate resulted compared with those in controls. Multinucleated giant cells (MGCs) that engulfed fungal cells were significantly increased in the lungs of immunized mice. Interleukin 17A (IL-17A)-, gamma interferon (IFN-γ)-, and tumor necrosis factor alpha (TNF-α)-producing lymphocytes were significantly increased in the spleens and lungs of immunized mice. The protective effect of this DC vaccine was significantly reduced in IFN-γ knockout mice. These results demonstrated that an increase in cytokine-producing lymphocytes and the development of MGCs that engulfed fungal cells were associated with the protection against pulmonary infection with highly virulent C. gattii and suggested that IFN-γ may have been an important mediator for this vaccine-induced protection.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25644007      PMCID: PMC4363414          DOI: 10.1128/IAI.02827-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection.

Authors:  Sarah E Hardison; Karen L Wozniak; Jay K Kolls; Floyd L Wormley
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  Emergence of Cryptococcus gattii-- Pacific Northwest, 2004-2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-07-23       Impact factor: 17.586

3.  A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation.

Authors:  Silvia Bozza; Katia Perruccio; Claudia Montagnoli; Roberta Gaziano; Silvia Bellocchio; Emanuela Burchielli; Gabriel Nkwanyuo; Lucia Pitzurra; Andrea Velardi; Luigina Romani
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

4.  Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak.

Authors:  James A Fraser; Steven S Giles; Emily C Wenink; Scarlett G Geunes-Boyer; Jo Rae Wright; Stephanie Diezmann; Andria Allen; Jason E Stajich; Fred S Dietrich; John R Perfect; Joseph Heitman
Journal:  Nature       Date:  2005-10-09       Impact factor: 49.962

5.  Recapitulation of the sexual cycle of the primary fungal pathogen Cryptococcus neoformans var. gattii: implications for an outbreak on Vancouver Island, Canada.

Authors:  James A Fraser; Ryan L Subaran; Connie B Nichols; Joseph Heitman
Journal:  Eukaryot Cell       Date:  2003-10

6.  PPARgamma deficiency results in reduced lung elastic recoil and abnormalities in airspace distribution.

Authors:  Dawn M Simon; Larry W Tsai; Edward P Ingenito; Barry C Starcher; Thomas J Mariani
Journal:  Respir Res       Date:  2010-06-02

7.  Extracellular fibrils of pathogenic yeast Cryptococcus gattii are important for ecological niche, murine virulence and human neutrophil interactions.

Authors:  Deborah J Springer; Ping Ren; Ramesh Raina; Yimin Dong; Melissa J Behr; Bruce F McEwen; Samuel S Bowser; William A Samsonoff; Sudha Chaturvedi; Vishnu Chaturvedi
Journal:  PLoS One       Date:  2010-06-07       Impact factor: 3.240

8.  The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation.

Authors:  Anna Vecchiarelli; Donatella Pietrella; Patrizia Lupo; Francesco Bistoni; Diane C McFadden; Arturo Casadevall
Journal:  J Leukoc Biol       Date:  2003-09       Impact factor: 4.962

9.  Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan.

Authors:  Lauren E Yauch; Jennifer S Lam; Stuart M Levitz
Journal:  PLoS Pathog       Date:  2006-11       Impact factor: 6.823

10.  Vaccine-mediated immune responses to experimental pulmonary Cryptococcus gattii infection in mice.

Authors:  Ashok K Chaturvedi; Rumanasma S Hameed; Karen L Wozniak; Camaron R Hole; Chrissy M Leopold Wager; Susan T Weintraub; Jose L Lopez-Ribot; Floyd L Wormley
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

View more
  9 in total

1.  Host response to pulmonary fungal infections: A highlight on cell-driven immunity to Cryptococcus species and Aspergillus fumigatus.

Authors:  Orchi Dutta; Jorge A Masso-Silva; Keyi Wang; Amariliz Rivera
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

Review 2.  Antiviral Cell Products against COVID-19: Learning Lessons from Previous Research in Anti-Infective Cell-Based Agents.

Authors:  Irina Chikileva; Irina Shubina; Anzhelika-Mariia Burtseva; Kirill Kirgizov; Nara Stepanyan; Svetlana Varfolomeeva; Mikhail Kiselevskiy
Journal:  Biomedicines       Date:  2022-04-07

Review 3.  Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome.

Authors:  Chrissy M Leopold Wager; Camaron R Hole; Karen L Wozniak; Floyd L Wormley
Journal:  Front Microbiol       Date:  2016-02-09       Impact factor: 5.640

4.  Dendritic Cells Primed with Paracoccidioides brasiliensis Peptide P10 Are Therapeutic in Immunosuppressed Mice with Paracoccidioidomycosis.

Authors:  Leandro B R Silva; Lucas S Dias; Glauce M G Rittner; Julián E Muñoz; Ana C O Souza; Joshua D Nosanchuk; Luiz R Travassos; Carlos P Taborda
Journal:  Front Microbiol       Date:  2017-06-14       Impact factor: 5.640

5.  Cryptococcus gattii alters immunostimulatory potential in response to the environment.

Authors:  Keigo Ueno; Yoshiko Otani; Nao Yanagihara; Takumi Nakamura; Kiminori Shimizu; Satoshi Yamagoe; Yoshitsugu Miyazaki
Journal:  PLoS One       Date:  2019-08-09       Impact factor: 3.240

6.  Phagosomal F-Actin Retention by Cryptococcus gattii Induces Dendritic Cell Immunoparalysis.

Authors:  Khusraw Jamil; Maria J Polyak; David D Feehan; Philip Surmanowicz; Danuta Stack; Shu Shun Li; Henry Ogbomo; Michal Olszewski; Anutosh Ganguly; Christopher H Mody
Journal:  mBio       Date:  2020-11-24       Impact factor: 7.867

Review 7.  T cell responses to control fungal infection in an immunological memory lens.

Authors:  Jaishree Sharma; Srinivasu Mudalagiriyappa; Som Gowda Nanjappa
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

8.  Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure.

Authors:  Makoto Urai; Yukihiro Kaneko; Keigo Ueno; Yoichiro Okubo; Tomoko Aizawa; Hidesuke Fukazawa; Takashi Sugita; Hideaki Ohno; Kazutoshi Shibuya; Yuki Kinjo; Yoshitsugu Miyazaki
Journal:  Front Cell Infect Microbiol       Date:  2016-01-06       Impact factor: 5.293

Review 9.  Interactions of Cryptococcus with Dendritic Cells.

Authors:  Karen L Wozniak
Journal:  J Fungi (Basel)       Date:  2018-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.